- Home
- RNXT vs TVRD Comparison
RNXT vs TVRD Comparison
Compare RNXT & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RNXT | TVRD |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.4M | 36.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | RNXT | TVRD |
|---|---|---|
| Price | $0.96 | $3.62 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $8.00 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 256.3K | 35.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.60 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,000.00 | N/A |
| Revenue This Year | $2,995.35 | N/A |
| Revenue Next Year | $219.61 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $3.50 |
| 52 Week High | $1.45 | $43.65 |
Technical Indicators
Market Signals| Indicator | RNXT | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 57.24 | 40.04 |
| Support Level | $0.78 | N/A |
| Resistance Level | $1.07 | $4.39 |
| Average True Range (ATR) | 0.07 | 0.23 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 67.89 | 3.92 |
Price Performance
Historical ComparisonAbout RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.